Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Pyxis Oncology prices $110 million stock and warrant offering for MICVO trialOct 1FinancingPyxis Oncology, IncUpdated
Pyxis Oncology closes $102.8 million public offering tied to MICVO dataOct 1FinancingPyxis Oncology, Inc
Pyxis Oncology terminates $150 million at-the-market stock offeringSep 29FinancingPyxis Oncology, Inc
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc
Pyxis Oncology reaffirms MICVO data timelines, closes $50 million private placementAug 13Quarterly updatePyxis Oncology, Inc
Pyxis Oncology announces up to $114 million private placement for MICVO programJul 2FinancingPyxis Oncology, Inc